Slide 1

R&D | Innovative Medicines | CNSP iMed AstraZeneca Translational Science Centre AZ-Karolinska Institutet Joint Research Program in Translational Science Hugh Salter az-tsc-karolinska@astrazeneca.com Slide 2 Hugh Salter Head TSC Lars Farde PET Lab Head & Clinical Director Magnus Ivarsson Neurophysiology Lab Head Ina Schuppe Koistinen Biochemical Biom. Lab Head Carina Jgenstedt Bismut Administrator Elin berg EEG Scientist Vacant AZ Postdoc Ying Sun AZ Postdoc Anna Mattsson AZ Postdoc Peter Johnstrm PET Radiochemist Magnus Schou PET Radiochemist Eva Lindstrm B PET Project Manager Aurelija Jucaite PET Clinical Scientist Zsolt Cselenyi PET Clinical Scientist Anna Bogstedt Biomarker Assays Susanna Eketjll Biomarker Assays Kina Hglund Biomarker Discovery Maria Bhat Biomarker Discovery AZ Translational Science Centre @ Karolinska Institutet SciLifeLab KS PET Centre Slide 3 R&D | Innovative Medicines | CNSP iMed Alzheimers disease Finding the right patients prodromal AD Selection of patients at appropriate disease stage Identifcation of prognostic markers + using these appropriately Enabling simple/peripheral measurement of central effects Slide 4 R&D | Innovative Medicines | CNSP iMed AZ TSC, joint research and the Neuroscience iMED Cambridge USCambridge UK Internal / external partners CRO, Consultancies. Biotech, Academia AZ Translational Science Centre, KI KI/AZ Joint Research Program in Translational Science 11 joint research programs, in place Q1-2013 [4 MUSD/yr] AZ Neuroscience Innovative Medicines KI/AZ/UU/SU/KTH SciLifeLab Research Program 10 research programs, inititating Q3-2013 [10 MUSD/yr] Centrumbildning CNS JRC Jan Hillert, Anna Wedell, Lars Klareskog, Hugh Salter, Lars Farde, Ina Schuppe, Magnus Ivarsson Steering group Jan Andersson, Gunnar von Heijne, Sofia Hober, Britt Skogseid, Anders Ekblom Slide 5 R&D | Innovative Medicines | CNSP iMed AZ-KI Translational Science Centre Joint Research Committee KI : Profs. Anna Wedell, Lars Klareskog, Jan Hillert AZ : Hugh Salter, Ina Schuppe Koistinen, Lars Farde, Magnus Ivarsson JRC is quorate when cochairs or their representatives are present Budget approval Approval of scientific reports / agreement on achievements Conflict resolution (publications, IP) Scope and mechanism for next funding call (2015) Project governance Scientific report once per year Financial report once per year, yearly payment of budget to host institution see instructions in information folder. Program co-ordinator Ina Schuppe Koistinen Administration Carina Jgenstedt Bismut Slide 6 R&D | Innovative Medicines | CNSP iMed KI-AZ Translational Science Centre Centre budget Fixed component (6 MSEK / yr) infrastructure Rent, animal facilities Workshops Attendance of postdocs/students to AZ postdoc conferences Central analysis staff???? Research component (24 MSEK / yr) staff + consumables Only 80% pre-allocated (4 yr projects, 5 yr funding) Grants to PIs What happens in 2015? Competitive renewal of current programs New grant call for additional 2 year programs Slide 7 R&D | Innovative Medicines | CNSP iMed Platforms at the Science for Life Laboratories, Stockholm A national resource centre for technology-driven bioscience Genomics / 2nd generation sequencing Proteomics siRNA screening Biosample immunoscreening (histo + biofluids) High-resolution microscopy Chemical biology Bioinformatics High content biology from 2013 Drug discovery Protein production Structural biology Genetic models Slide 8 R&D | Innovative Medicines | CNSP iMed AZ-KI Joint Research Program in TS : 2013 Projects Per-Johan JakobssonMedicineIdentification of sub-phenotypes and biomarkers in systemic autoimmune diseases Sven-Erik DahlnIMM, CfA New biomarker patterns for phenotyping of asthma, allergies and COPD Mauro D'Amato BioNut Post-genomic applications in IBD: exploitation of genetic information toward improved diagnosis and therapy Johan Bjrkegren MBB DNA-on/DNA-offtowards biomarkers predicting molecular disease states driving coronary artery disease in subgroups of patients Ulf AnderssonCMM Development of assays to quantify HMGB1 isoform levels as biomarkers for mode of cell death and clinical prognosis in drug-induced liver injury (DILI) Henrik Grnberg MEB Circulating tumor DNA as a personalized biomarker for treatment prediction and disease monitoring in prostate and breast cancer Jonas BerghOnc-Pat Search and identification of therapy predictive markers in primary and metastatic breast cancer with focus on TORC1/2 inhibition and AZD8931 with long-term goals of individual prognostication and tailored therapy selections Janne LehtiOncPat Immediate adaptation analysis for prediction of efficient combination therapy with Gefitinib Roman Zubarev, Agneta Nordberg, Dag Aarsland MBB Discovery of diagnostic and prognostic biomarkers of preclinical Alzheimers disease by combining advanced proteomics, metabolomics and lipidomics analyses of blood plasma and cerebrospinal fluid Sophie Erhardt PhyPha The pursuit of immune biomarkers in schizophrenia tracking down pathophysiological mechanisms Per Svenningsson CNSBiomarkers of early Parkinsons disease R&I CVGI Safety Onco NS